Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer

Increasing duration of tamoxifen therapy improves survival in women with breast cancer but the impact of adherence to tamoxifen on mortality is unclear. This study investigated whether women prescribed tamoxifen after surgery for breast cancer adhered to their prescription and whether adherence influenced survival. A retrospective cohort study of all women with incident breast cancer in the Tayside region of Scotland between 1993 and 2002 was linked to encashed prescription records to calculate adherence to tamoxifen. Survival analysis was used to determine the effect of adherence on all-cause mortality. In all 2080 patients formed the study cohort with 1633 (79%) prescribed tamoxifen. The median duration of use was 2.42 years (IQR=1.04–4.89 years). Longer duration was associated with better survival but this varied over time. The hazard ratio for mortality in relation to duration at 2.4 years was 0.85, 95% CI=0.83–0.87. Median adherence to tamoxifen was 93% (interquartile range=84–100%). Adherence <80% was associated with poorer survival, hazard ratio 1.10, 95% CI=1.001–1.21. Persistence with tamoxifen was modest with only 49% continuing therapy for 5 years of those followed up for 5 years or more. Increased duration of tamoxifen reduces the risk of death, although one in two women do not complete the recommended 5-year course of treatment. A significant proportion of women have low adherence to tamoxifen and are at increased risk of death.

[1]  R. Prescott,et al.  Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. , 1996, British Journal of Cancer.

[2]  Monica Morrow,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials , 2007 .

[3]  B Fisher,et al.  Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. , 1996, Journal of the National Cancer Institute.

[4]  Jerry Avorn,et al.  Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[6]  J. Bryant,et al.  Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. , 2001, Journal of the National Cancer Institute.

[7]  Matthew P Goetz,et al.  Early discontinuation of tamoxifen , 2007, Cancer.

[8]  T. Lash,et al.  Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Love,et al.  Survival Analysis Part III: Multivariate data analysis – choosing a model and assessing its adequacy and fit , 2003, British Journal of Cancer.

[10]  V. Carstairs,et al.  Deprivation and health in Scotland. , 1990, Health bulletin.

[11]  Aliza K Fink,et al.  Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group. , 1996, Journal of the National Cancer Institute.

[13]  M. Dimatteo.  Variations in Patients’ Adherence to Medical Recommendations: A Quantitative Review of 50 Years of Research , 2004, Medical care.

[14]  P. Donnan,et al.  Propensity score methods in drug safety studies: practice, strengths and limitations , 2001, Pharmacoepidemiology and drug safety.

[15]  S. Legha,et al.  Tamoxifen in the treatment of breast cancer. , 1988, Annals of internal medicine.

[16]  E. Grunfeld,et al.  Adherence beliefs among breast cancer patients taking tamoxifen. , 2005, Patient education and counseling.

[17]  P. Thompson,et al.  Magnetic resonance imaging of left atrial thrombus , 2002, Heart.

[18]  Theodore T. Suh,et al.  Mentoring junior faculty in geriatric oncology: report from the Cancer and Aging Research Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Collins,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[20]  A. Lippman.  Adherence to medication. , 2005, The New England journal of medicine.

[21]  M. Carcangiu.  Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.

[22]  Osborne Ck,et al.  Tamoxifen in the Treatment of Breast Cancer , 1998 .

[23]  H. Quan,et al.  New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. , 2004, Journal of clinical epidemiology.

[24]  Catherine Legrand.  1687Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials : Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , 2005 .

[25]  R. Chlebowski,et al.  Adherence to Endocrine Therapy for Breast Cancer , 2007, Oncology.

[26]  Rajiv Sarin,et al.  Tamoxifen non-compliance: does it matter? , 2002, The Lancet. Oncology.

[27]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[28]  T. Lash,et al.  Mortality impact of less-than-standard therapy in older breast cancer patients. , 2008, Journal of the American College of Surgeons.

[29]  C. Redmond,et al.  Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.

[30]  C. Bryce,et al.  Tamoxifen in early breast cancer , 1998, The Lancet.

[31]  Timothy L Lash,et al.  Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  H. Mcdonald,et al.  Interventions to enhance patient adherence to medication prescriptions: scientific review. , 2002, JAMA.

[33]  E. Winer,et al.  Primary care for survivors of breast cancer. , 2000, The New England journal of medicine.

[34]  K. Bennett,et al.  Early discontinuation of tamoxifen , 2007, Cancer.

[35]  T G Clark,et al.  Survival Analysis Part I: Basic concepts and first analyses , 2003, British Journal of Cancer.